Healthcare
Live Price
Offline$15.88
+2.06% today
1Y Change
+336.22%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Relay Therapeutics, Inc. (RLAY) is a Healthcare stock with a market cap of $2.27B and listed on NASDAQ. The stock last traded around $15.88 and up 336.2% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +53.4%, EPS growth of +31.8%, a dividend yield of 0.0%. What stands out right now is revenue +53.4%, EPS +31.8%, free cash flow +6.1% with operating margin -1971.5% and ROIC -50.5%. Valuation already assumes a fairly strong business story at price/sales 148.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RLAY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLAY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RLAY Max Drawdown
-28.15%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RLAY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.0M
+119.3% YoY
FY Net Income
-$363.9M
-25.3% YoY
Free Cash Flow
-$77.9M
+67.4% YoY
Revenue Growth
+53.4%
EPS Growth
+31.8%
Gross Margin
91.2%
Net Margin
-1800.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 15M | 10M | 26M | 1M | 3M |
| Gross Profit | 12M | 10M | 26M | 1M | 3M |
| Operating Income | -303M | -372M | -373M | -299M | -365M |
| EBITDA | -273M | -380M | -374M | -307M | -223M |
| Net Income | -276M | -338M | -342M | -291M | -364M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84M | 124M | 144M | 999M | 280M |
| Total Assets | 621M | 871M | 844M | 1.1B | 1.0B |
| Total Liabilities | 54M | 94M | 92M | 150M | 111M |
| Shareholder Equity | 567M | 778M | 752M | 950M | 898M |
| Total Debt | 32M | 49M | 53M | 58M | 23M |
| Net Debt | -52M | -76M | -90M | -941M | -257M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
74M
+67.6% YoY
Capital Expenditures
3M
+61.7% YoY
Free Cash Flow
78M
+67.4% YoY
Key ratios
Gross Margin
91.2%
Operating Margin
-1971.5%
Net Margin
-1800.5%
ROE
-43.2%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.